| Urinary tract infection
Zemdri vs Zerbaxa
Side-by-side clinical, coverage, and cost comparison for urinary tract infection.Deep comparison between: Zemdri (Plazomicin) vs Zerbaxa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZerbaxa has a higher rate of injection site reactions vs Zemdri (Plazomicin) based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zerbaxa but not Zemdri (Plazomicin), including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zemdri (Plazomicin)
Zerbaxa
At A Glance
IV infusion
Every 24 hours
Aminoglycoside
IV infusion
Every 8 hours
Cephalosporin/beta-lactamase inhibitor
Indications
- Urinary tract infection
- Peritonitis
- Urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- VABP
Dosing
Urinary tract infection 15 mg/kg every 24 hours by IV infusion over 30 minutes for 4 to 7 days in adults with CLcr >=90 mL/min; dose reduced to 10 mg/kg every 24 hours (CLcr 30 to <90 mL/min) or 10 mg/kg every 48 hours (CLcr 15 to <30 mL/min).
Peritonitis 1.5 g IV every 8 hours over 1 hour for 4 to 14 days, used in conjunction with metronidazole 500 mg IV every 8 hours; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 5 to 14 days.
Urinary tract infection, Pyelonephritis 1.5 g IV every 8 hours over 1 hour for 7 days; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 7 to 14 days.
Hospital acquired pneumonia, VABP 3 g IV every 8 hours over 1 hour for 8 to 14 days in adult patients 18 years and older.
Contraindications
- Known hypersensitivity to any aminoglycoside
- Known serious hypersensitivity to components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class
Adverse Reactions
Most common (>=1%) Decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, hypotension
Serious Nephrotoxicity, ototoxicity, neuromuscular blockade, fetal harm, hypersensitivity reactions, Clostridium difficile-associated diarrhea
Most common (>=5%) Nausea, diarrhea, headache, pyrexia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea, intracranial hemorrhage, renal impairment/renal failure, hepatic transaminase increased
Pharmacology
Plazomicin is an aminoglycoside antibacterial that binds to the bacterial 30S ribosomal subunit, inhibiting protein synthesis with concentration-dependent bactericidal activity against Enterobacteriaceae.
Ceftolozane is a cephalosporin antibacterial that inhibits bacterial cell wall biosynthesis by binding to penicillin-binding proteins (PBPs); tazobactam is an irreversible beta-lactamase inhibitor that extends ceftolozane activity against beta-lactamase-producing organisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zemdri (Plazomicin)
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
Zerbaxa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Zemdri (Plazomicin)
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zerbaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zemdri (Plazomicin)
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Zerbaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zemdri (Plazomicin).
No savings programs available for Zerbaxa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Zemdri (Plazomicin)View full Zemdri (Plazomicin) profile
ZerbaxaView full Zerbaxa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.